Test Archives

NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)

June 1, 2022
REHOVOT, Israel

REHOVOT, ISRAEL- June 1, 2022  

NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced today the successful completion of the first stage of a Simon 2 stage Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). The patients were treated with NAP (10 μg/kg/day x 4, days 1-4) and with docetaxel 75mg/m2, on day 5. The first stage of this trial required a minimum of two responses out of ten patients and the second stage is now enrolling.

 “These early observations are encouraging as patients with advanced disease previously treated with chemotherapy and checkpoint inhibitors have limited treatment options and new alternatives are needed. In addition, this clinical milestone occurs just as the acquisition of InterX has been recently completed, adding a computer-aided drug discovery arm (CADD) to the pre-clinical and clinical capabilities of NeoTX. So, this has been a crucial time for us” said Asher Nathan, CEO of NeoTX. “NeoTX’s drug discovery capabilities are strengthened by a world-class team that includes three Nobel Laureates. InterX technologies have the potential to significantly increase the speed of drug discovery. InterX also provided a pipeline that includes an oral PD-L1 inhibitor, which aligns with our current development plan of investigating NAP in combination with CPIs in various indications.”

 

About NeoTX

NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors: NCT03983954, and NCT04880863. NeoTX’s computer aided drug discovery (CADD) subsidiary utilizes groundbreaking technology to dramatically decrease drug discovery times. . For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com
+1 609-718-2305 x204
+972 3 912 5853 x204

NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM

May 12, 2022
REHOVOT, Israel
REHOVOT and TEL AVIV, ISRAEL; MENLO PARK and BERKELEY, CALIFORNIA.  — May 12, 2022 – NeoTX announced today the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt’s discoveries. These tools allow a detailed quantum mechanical process assessment of biochemical interactions resulting in faster, more accurate and efficient drug discovery. In addition to the discovery engine, this acquisition also comes with a pipeline of early drugs. “We are excited to be expanding NeoTX capabilities to include a suite of proprietary drug discovery technologies. InterX is a world class team that includes three Nobel Laureates who have developed technologies that have the potential to increase the speed of drug discovery. These technologies augment traditional Computer Assisted Drug Discovery (CADD) and are designed to replace much of the typical synthesis and testing cycles that are needed after obtaining results from the traditional CADD process, while potentially saving three-plus years of the typical drug discovery timeline” said CEO, Asher Nathan. “InterX’s technology is the most advanced in the industry, and when combined with the development expertise of NeoTX, we will be able to advance best-in-class drug candidates, increase the value of our pipeline, and strive to contribute to improvement of quality of life within society,” said Nobel Prize Laureate Prof. Roger Kornberg, Chief Scientist of NeoTX and cofounder of InterX. InterX will benefit from the experience and infrastructure of NeoTX while maintaining a culture of innovation and creativity. Post-merger, Prof. Kornberg has also assumed the role of Chairman of the Board of NeoTX. About NeoTX NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com About InterX InterX is a drug development company, based in the United States and Israel, which is revolutionizing biomolecular computation of chemical and biological systems. The company aims to achieve robust and accurate prediction of molecular and ensemble properties of biological systems using computational methods. InterX is led by Nobel Prize-winning scientist Roger Kornberg. For more information, please visit www.interx.dev   Media Contact: Aviram Uzi Head of PR and Communications Gelbart-Kahana Investor Relations aviram@gk-biz.com +972-525329103   Investor Contact: Robert Harow, CFOO NeoTX Therapeutics Ltd robert@neotx.com 609-718-2305 x204  

NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer

January 31, 2022
REHOVOT, Israel

Rehovot, Israel — Jan 31, 2022 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced the promotion of current CMO, Marcel Rozencweig, M.D., to President and the appointment of Scott Z. Fields, M.D., as the new chief medical officer, effective tomorrow, Feb 01, 2022.   Dr. Fields brings more than 30 years of experience in clinical drug development and has been previously the Senior Vice President and Pharmaceutical Development Head, Oncology at Bayer Pharmaceuticals (OTC: BAYRY). 645382

“We are thrilled that Marcel will be the President to lead NeoTX in its next chapter of growth and success.  He has been a key part of NeoTX growth since its inception and, in his new role as President, will help to accelerate growth and expand strategic industry partnerships” said Asher Nathan, Ph.D., chief executive officer of NeoTX.

“I am very pleased and looking forward to leading, as President, in NeoTX’s advancement” said Dr. Rozencweig.  “Additionally, as a founding member of NeoTX, it gives me great pleasure to welcome Dr. Fields to our leadership team.”

“We, at NeoTX, are delighted that Scott is bringing his strong industry and operational leadership, which will prove valuable for our clinical development and registration strategies.  His broad experience in oncology drug development, with over a dozen drug approvals, is an excellent fit with our vision.” said Asher Nathan, Ph.D., chief executive officer of NeoTX.

“I’m thrilled to join NeoTX at this time of important growth and evolution of the company,” said Dr. Fields. “Together with our experienced leadership team, I look forward to helping the company accelerate the development of our pipeline and bring innovative new medicines to patients.”

As Global Head of Development for Oncology at Bayer Pharmaceuticals, Dr. Fields was responsible for early and late-stage development including several novel oncology medicines across the platforms for targeted therapies/precision medicine, antibody drug/alpha radiation conjugates and novel Immuno-Oncology agents. His group was responsible for the development and global registration of Darolutamide – a next generation androgen receptor inhibitor for prostate cancer and with partner Loxo, for Larotrectinb – a tissue agnostic NTRK inhibitor.  He was also responsible for the Oncology Operations, Project Management, Regulatory, Biomarkers, Biostatistics and Medical Writing groups. Prior to his position at Bayer, Dr. Fields held senior positions at Vertex Pharmaceuticals (NASDAQ: VRTX), SmithKline Beecham (NYSE: GSK), Amgen (NASDAQ: AMGN), Eisai (OTC: ESALY), and Arno Therapeutics (OTC: ARNI) and helped bring over a dozen drugs to market. He also practiced oncology/hematology and transplant medicine in academic settings.  Dr. Fields received his medical degree from SUNY Downstate Medical Center in New York, followed by training in internal medicine, hematology and oncology at Columbia University Medical Center.

 

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for non-small cell lung cancer and other solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi

Head of PR and Communications

Gelbart-Kahana Investor Relations

aviram@gk-biz.com

+972-525329103

 

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

 

Data on Naptumomab Estafenatox (NAP) Enhancing CAR-T cells Potency Presented by NeoTX at SITC 2021 Annual Meeting.

November 30, 2021
REHOVOT, Israel

Rehovot, Israel — November 30, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced that the preclinical data on naptumomab estafenatox (NAP) enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting at the Walter E. Washington Convention Center, Washington D.C.

Clinical CAR-T therapy currently has limited efficacy against solid tumors due to low trafficking to the tumor, limited cell expansion in patients, tumor antigen heterogeneity, and an immunosuppressive microenvironment. NeoTX presented data that shows that NAP generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro. NAP is a fusion protein that consists of genetically engineered Superantigens (Sag) linked to Fragment antigen-binding (Fab) moieties directed to tumor-associated antigens, turns “cold tumors hot” and, in preclinical models, can lead to long-term memory responses.

The ability of NAP administration to activate T cells outside of the immunosuppressive microenvironment, promote T cell infiltration into the tumor and induce long-term memory responses strongly suggests that the combination of CAR-T cells with NAP may overcome the limited effect of CAR-T therapy against solid tumors. To access the presented poster, please click here.

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for non-small cell lung cancer and other solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

November 9, 2021
REHOVOT, Israel

REHOVOT, Israel – November 9, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, today announced a presentation on the company’s lead program, naptumomab estafenatox (NAP), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center, Washington D.C.  The poster presentation will highlight preclinical data demonstrating that NAP enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.

Details on the poster presentation are as follows:

  • Title: Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors
  • Abstract Number: 576 (ePoster)
  • Lead Author: Yael Sagi, Ph.D.
  • Category: Combination Immunotherapies
  • Date & Time: The ePoster will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com 
609-718-2305 x204

NeoTX Announces First Patient Enrolled In Phase 2a Clinical Trial Of Naptumomab Estafenatox (NAP), Its Lead Tumor Targeted Superantigen (TTS) Candidate, In Combination With Docetaxel In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

October 20, 2021
REHOVOT, Israel

REHOVOT, Israel – October 20, 2021 – NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that the first patient has been enrolled in the company’s phase 2a clinical trial of naptumomab estafenatox (NAP), its lead Tumor Targeted Superantigen (TTS) candidate, in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).

 “Dosing of the first patient in this phase 2 trial represents a crucial step forward for the clinical advancement of NAP” said Asher Nathan, Ph.D., chief executive officer of Neo TX. “This trial is based on promising phase 1 data. NSCLC is one of the deadliest cancers, and we are looking forward to evaluating NAP in this setting”.

 The phase 2a, open label trial in the US, will assess NAP in combination with docetaxel in patients who had been previously treated with checkpoint inhibitors and have advanced or metastatic NSCLC.  The primary endpoint is objective response rate as measured by RECIST 1.1 criteria.  The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics, and pharmacodynamics. For more information about the trial, visit https://clinicaltrials.gov/ct2/show/NCT04880863

 

About NeoTX

NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com

 

Media Contact:
Aviram Uzi
Head of PR and Communications
Gelbart-Kahana Investor Relations
aviram@gk-biz.com
+972-525329103

Investor Contact:
Robert Harow, CFOO
NeoTX Therapeutics Ltd
robert@neotx.com
609- 718-2305